[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The University of Texas Health Science Center at San Antonio\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":645},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,85,0,25,[9,47,75,104,132,160,184,208,234,258,288,311,334,353,372,388,413,439,463,490,514,540,568,595,619],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652826","genetic-of-skeletal-muscle-insulin-resistance-100652826",false,"NCT07780513","Genetic of Skeletal Muscle Insulin Resistance","Identification of Cell Type-Specific Insulin Responsive Quantitative Trait Loci in Human Skeletal Muscle","Inclusion Criteria:\n\n* Males and Females Age 18-75\n* Body Mass Index (BMI) \\> 18\n* Normal glucose tolerance as defined by:\n\nFasting blood sugar \\\u003C 100 mg\u002FdL 2-hour Oral Glucose Tolerance Test (OGTT) \\\u003C 140mg\u002FdL Stable weight over the past 3 months defined as \\>±5% change in body weight\n\n* Hemoglobin A1c \\\u003C 5.7\n* Creatinine \\\u003C 2\n* Aspartate aminotransferase\u002FAlanine transaminase (AST\u002FALT) \\\u003C 75\n* Blood sodium 135 to 145 mEq\u002FL\n* Blood potassium 3.6 to 5.2 mmol\u002FL\\[MH1.1\\]\n\nExclusion Criteria:\n\n* Urine albumin excretion\\>300mg\u002Fday\n* Partial thromboplastin time (PTT) \\>35International normalized ratio (INR) \\> 1.2\n* No oral corticosteroids for 1 month\n* No Sodium-glucose co-transporter 2 (SGLT2) inhibitor for 3 months\n* No glucagon-like peptide-1 (GLP-1) receptor agonist for 6 months\n* Any anti-platelet or anti-coagulation medication other than as needed for Pain Management\n* No alcohol 4 days before the insulin clamp and biopsy procedure\n* No acute structural knee injuries\n* No Rheumatologic muscular or nervous system disease\n* Pregnancy, Intentions to become pregnant, or Breastfeeding\n* Blood Pressure \\>170\u002F110\n* Temperature \\> 100F\n* Triglycerides \\> 400 by lipid panel\n* Hemoglobin \\\u003C10g\u002FdL\n* 1+ or greater Blood on Urinalysis\n* 2+ or greater Protein on Urinalysis\n* Electrocardiogram (EKG) abnormalities, including but not limited to ST elevations, T wave abnormalities, evidence of recent prior infarct",true,"ALL","18 Years","75 Years",{"count":22,"type":23},100,"ESTIMATED","INTERVENTIONAL",[26],"NA","In this study, we will use euglycemic\u002Fhyperinsulinemic clamps, longitudinal skeletal muscle biopsies, and single nucleus RNA- and ATAC- sequencing to reveal cell type-specific molecular response Quantitative trait loci (rQTLs) acutely regulated by insulin signaling and glucose uptake.",[29],"Insulin Stimulated",[31,32,33],"Insulin","Skeletal muscle","Quantitative trait loci (QTL)","RECRUITING","2026-08-18",{"date":37,"type":38},"2026-08-21","ACTUAL",{"date":40,"type":23},"2026-08-31",{"date":42,"type":23},"2031-07-31",{"name":44,"class":45},"The University of Texas Health Science Center at San Antonio","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100589382","shared-decision-making-in-ptsd-treatment-100589382","NCT06953687","Shared Decision Making in PTSD Treatment","Implementing and Evaluating a Patient-Centered PTSD Treatment Program for Military Personnel","Inclusion Criteria:\n\n1. Adult active duty military service members aged 18 or older.\n2. Meets diagnostic criteria for PTSD based on the Clinician Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders-5 (CAPS-5).\n\nExclusion Criteria:\n\n1. Acute suicidality or homicidality requiring immediate intervention, such as hospitalization.\n2. Moderate to severe brain injury as assessed by the History of Head Injury Form\n3. Severe alcohol consumption patterns as assessed using the Alcohol Use Disorders Identification Test and warranting immediate intervention as determined by clinical judgement.\n4. Experiencing active psychosis or mania as determined by scores on the Prodromal Questionnaire and Mood Disorder Questionnaire in combination with clinical judgement.",{"count":55,"type":23},200,[26],"The purpose of this research study is to learn about how Shared Decision Making, when used to decide treatment, impacts treatment engagement, retention, and outcomes for active duty military personnel seeking treatment for posttraumatic stress disorder (PTSD).\n\nShared Decision Making between the service member and the therapists will be used to match patients to 1 of 3 different types of therapy for PTSD: (1) Prolonged Exposure (PE) therapy, (2) Cognitive Processing Therapy (CPT), or (3) Written Exposure Therapy (WET) in 1 of 2 different frequencies: (1) massed (daily) or (2) spaced (weekly).",[59],"Post Traumatic Stress Disorder PTSD",[61,62,63,64,65],"Shared Decision Making","Patient Characteristics","Patient Treatment preference","Treatment engagement","Treatment outcomes","2026-08-17",{"date":68,"type":38},"2026-08-19",{"date":70,"type":38},"2025-05-09",{"date":72,"type":23},"2028-09",{"name":44,"class":45},2,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":74},"100462716","phase-4-quantifying-hepatic-mitochondrial-fluxes-in-humans-100462716","NCT05305287","Quantifying Hepatic Mitochondrial Fluxes in Humans","Quantitation of Hepatic Mitochondrial Fluxes in Humans With Nonalcoholic Fatty Liver Disease (NAFLD)","T2D with NAFL\n\nInclusion Criteria:\n\n* Confirmed T2D based on OGTT (2 h glucose ≥200 mg\u002Fdl).\n* Treated with diet, metformin, and\u002For sulfonylurea and in good general health determined by medical history, physical exam, and routine blood chemistries;\n* age = 18-80 years;\n* BMI = 25-40 kg\u002Fm2;\n* HbA1c = 7-10%; stable body weight (±4 pounds) over the preceding 3-months;\n* not taking any medication known to affect glucose metabolism other than antidiabetic medications.\n* Evidence of moderate\u002Fsevere fatty liver (steatosis; grade S2\u002FS3 on FibroScan corresponding to ≥10% fat on MRI-PDFF) and no\u002Fminimal hepatic fibrosis (grade F0\u002FF1 on FibroScan).\n\nExclusion Criteria:\n\n* Alcohol consumption \\>14 units\u002Fweek for women and \\>21 units\u002Fweek for men.\n* Liver cirrhosis (fibrosis stage 4).\n* Evidence of other forms of chronic liver disease, including alcoholic liver disease, hepatitis B and C, primary biliary cholangitis, suspected\u002Fproven liver cancer and any other liver disease other than NAFLD.\n* Type 1 diabetes and\u002For GAD positive subjects.\n* Subjects not drug naive or have been on metformin more than 3 months.\n* Presence of proliferative retinopathy.\n* Urine albumin excretion \\> 300 mg\u002Fday.\n* History of NY Class III-IV heart failure\n\nT2D with NASH\n\nInclusion Criteria:\n\n* Confirmed T2D based on OGTT (2 h glucose ≥200 mg\u002Fdl).\n* Treated with diet, metformin, and\u002For sulfonylurea and in good general health determined by medical history, physical exam, and routine blood chemistries;\n* age = 18-80 years;\n* BMI = 25-40 kg\u002Fm2;\n* HbA1c = 7-10%;\n* stable body weight (±4 pounds) over the preceding 3-months;\n* not taking any medication known to affect glucose metabolism other than antidiabetic medications.\n* Evidence of moderate\u002Fsevere fatty liver (steatosis; grade S2\u002FS3 on FibroScan corresponding to ≥10% liver fat on MRI-PDFF) and moderate\u002Fsevere hepatic fibrosis (grade F2\u002FF3 on FibroScan).\n\nExclusion Criteria:\n\n* Alcohol consumption \\>14 units\u002Fweek for women and \\>21 units\u002Fweek for men.\n* Liver cirrhosis (fibrosis stage 4).\n* Evidence of other forms of chronic liver disease, including alcoholic liver disease, hepatitis B and C, primary biliary cholangitis, suspected\u002Fproven liver cancer and any other liver disease other than NAFLD.\n* Type 1 diabetes and\u002For GAD positive subjects.\n* Subjects not drug naive or have been on metformin more than 3 months.\n* Presence of proliferative retinopathy.\n* Urine albumin excretion \\> 300 mg\u002Fday.\n* History of NY Class III-IV heart failure","80 Years",{"count":84,"type":23},60,[86],"PHASE4","In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone",[89,90,91],"Non-Alcoholic Fatty Liver Disease","Type 2 Diabetes","Mitochondrial Metabolism Disorders",[93,94,95,96],"NAFLD","Mitochondria","Type 2 diabetes","Insulin resistance","2026-08-12",{"date":66,"type":38},{"date":100,"type":38},"2022-11-01",{"date":102,"type":23},"2027-03-31",{"name":44,"class":45},{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":24,"phases":115,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":46},"100493458","early-phase-1-oral-intradialytic-amino-acid-supplementation-to-vitalize-end-stage-kidney-disease-patients-on-hemodialysis-100493458","NCT05705414","Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis","Oral Intradialytic Amino Acids Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis (OASIS)","OASIS","Inclusion Criteria:\n\n1. Male or Female\n2. Age 18-64 years\n3. Receiving 3 x weekly in clinic hemodialysis for at least 6 months\n\nExclusion Criteria:\n\n1. Hypersensitivity to amino acid(s) and\u002For any excipient\n2. Clinical documentation of COVID-19\n3. Concomitant intake of amino acids supplements\n4. Current use or abuse of alcohol, marijuana, narcotic, or other substances\n5. Heart failure receiving active management\n6. Malignant cancer receiving anticancer therapy\n7. Diagnosis of major depressive disorder receiving antidepressants\n8. Diagnosis of chronic liver disease\n9. Cerebrovascular disease with sequelae\n10. Upper limb amputation, osteoarthritis, or degenerative diseases of fingers, carpel tunnel syndrome in the non-fistula or graft hand preventing completion of hand grip strength test.","64 Years",{"count":114,"type":23},28,[116],"EARLY_PHASE1","The study will test and compare the efficacy of a single essential amino acid valine with a combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.",[119],"End Stage Renal Disease",[121,122,123],"Fatigue","End-stage kidney disease","Hemodialysis","2026-08-10",{"date":126,"type":38},"2026-08-11",{"date":128,"type":38},"2024-10-18",{"date":130,"type":23},"2026-12",{"name":44,"class":45},{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":18,"minAge":140,"maxAge":20,"enrollmentInfo":141,"targetDuration":4,"studyType":24,"phases":143,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":46},"100626547","early-phase-1-sarcopenia-in-chronic-kidney-disease-ckd-patients-100626547","NCT07437053","Sarcopenia in Chronic Kidney Disease (CKD) Patients","Branched-chain Amino Acids to Improve Sarcopenia in Patients With Advanced Chronic Kidney Disease (BOOST-CKD)","BOOST_CKD","Inclusion Criteria:\n\n1. Ability of participant to understand and the willingness to sign a written informed consent document.\n2. Males and females of age 45-75 yrs\n3. Hand grip strength of \\\u003C26 kg for male and \\\u003C16 kg for female\n4. Documented diagnosis of estimated glomerular filtration rate (eGFR) of ≤15 mL\u002Fmin\u002F1.73 m2, based on CKD-EPI serum-creatinine based formula in the past ≥3 months in absence of acute kidney injury.\n5. Not on dialysis and is not expected to initiate dialysis or any kidney replacement therapy in next 4 months\n6. Receiving standard of care including dietary recommendation for diabetes, hypertension, CKD, and other comorbidities\n7. Patients who are on an SGLT2-i or GLP-1 agonist should be on a stable dose for at least 3 months prior randomization, with no dose adjustments expected in the next 4 months\n8. Serum HCO3 concentration 20-29 mmol\u002FL based on two consecutive recent routine labs\n9. HbA1c 7-9% based on most recent routine lab\n10. Serum albumin ≥3.8 g\u002FdL based on most recent routine lab\n11. Blood hemoglobin ≥10 g\u002FdL based on most recent routine lab\n12. Willingness to adhere to lifestyle management, including diet and exercise as recommended by care providers, and to the study intervention, procedures, and regimen.\n\nExclusion Criteria:\n\n1. Any known history of hypersensitivity\u002Fintolerance to valine or specific amino acids\n2. Any condition that may indicate the individual is not \"metabolically stable\" which may include active infection, currently on systemic antibiotic, hospitalization within 2 weeks on consenting, active malignancy, on immunosuppressive agents, and unexplained significant weight loss during the past 3 months\n3. With a cardiac pacemaker and\u002For an implantable cardioverter-defibrillator\n4. Significant arthritis prohibiting strength test and walk gait speed test\n5. Significant comorbidities including heart failure (NY Class III or IV), neurological disorders, HIV AIDS, etiology of CKD other than diabetes and hypertension, or any condition that could compromise the subject's ability to study procedures as judged by study clinician\n6. Currently taking any protein supplements\n7. Pregnant, lactating, childbearing women\n8. History of Maple syrup urine disease (MSUD)\n9. Scheduled for kidney transplantation or dialysis in next 4 months\n10. Current participation in another interventional trial\n11. Documented noncompliance with regard to clinic visits, medications, and lifestyle management.\n12. Documentation of current or history of substance abuse.","45 Years",{"count":142,"type":23},20,[116],"Sarcopenia, or loss of muscle and strength is common in patients with poor kidney function. Although a high protein diet is generally recommended for sarcopenia, patients with poor kidney function are advised to follow a low-protein diet. In this study, we will evaluate the practicality and potential benefits of two different amino acids (molecules that form proteins) in improving sarcopenia in patients with advanced kidney disease.\n\nThe study aims to improve muscle mass and strength. All study procedures are free of cost and do not require significant time commitment. You will have time to ask questions and discuss the study with your family, primary care physician, and your kidney doctor to make the decision if this is right study for you to participate in.",[146,147],"Chronic Kidney Disease","Sarcopenia",[149,150,151],"Valine","Essential amino acid","Metabolic effects","NOT_YET_RECRUITING","2026-08-07",{"date":126,"type":38},{"date":156,"type":23},"2026-08-24",{"date":158,"type":23},"2027-10-30",{"name":44,"class":45},{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":18,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":24,"phases":172,"briefSummary":175,"conditions":176,"keywords":177,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":181,"leadSponsor":183,"locationsCount":46},"100562913","phase-1-bupropion-for-fatigue-in-end-stage-kidney-disease-patients-on-hemodialysis-100562913","NCT06609343","Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis","Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis (BRISK)","BRISK","Inclusion Criteria:\n\n1. Male and female ESKD patients between aged 25-74 yrs on maintenance in-center hemodialysis procedure 3 times\u002Fweek for ≥3 months with an arteriovenous fistula or graft.\n2. Blood hemoglobin of ≥10.0 g\u002FdL based on most recent routine laboratory profile.\n3. Dialysis adequacy measured with Kt\u002FV of ≥1.2\n4. Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n1. Currently on bupropion or hypersensitivity\u002F intolerance to bupropion by history and monoamine oxidase inhibitors.\n2. Diagnosis or history of eating disorders (bulimia or anorexia nervosa) and seizure.\n3. Pregnant, lactating, childbearing women\n4. History of post-acute COVID-19 syndrome\n5. Diagnosis of depression and\u002For on antidepressants and bipolar affective disorder\n6. Patient Health Questionnaire (PHQ)-9 score of ≥10\n7. Diagnosis of cognitive impairment including dementia\n8. Current participation in another interventional trial\n9. Scheduled for kidney transplantation in next 6 months\n10. Life expectancy \\\u003C6 months as judged by the attending nephrologist\u002Fprimary care physician.\n11. Current or history of substance abuse or dependency.","25 Years","74 Years",{"count":171,"type":23},16,[173,174],"PHASE1","PHASE2","Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of tiredness. As a result, patients continue to suffer with poor quality of life and impaired daily activities. The purpose of this pilot trial is to find out if bupropion (a medicine commonly prescribed for stopping smoking, seasonal mood disorder, and depression) may help lessen fatigue in hemodialysis patients.\n\nIn this study, hemodialysis participants will receive bupropion tablet orally three times a week during routine dialysis procedure for consecutive 8 weeks. Study participants will complete a battery of questionnaires to self-report fatigue, cognition, and quality of life. The study team will collect biological specimens. All these procedures will be performed at the dialysis clinic during routine dialysis procedure.",[119,121],[123,178],"Kidney dialysis",{"date":126,"type":38},{"date":156,"type":23},{"date":182,"type":23},"2027-01-30",{"name":44,"class":45},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":24,"phases":193,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":205,"leadSponsor":207,"locationsCount":46},"100619759","real-world-evaluation-of-the-effectiveness-and-implementation-of-a-digital-health-therapeutic-for-oud-100619759","NCT07348796","Real World Evaluation of the Effectiveness and Implementation of a Digital Health Therapeutic for OUD","Real World Evaluation of the Effectiveness and Implementation of a Digital Health Therapeutic for Opioid Use Disorder (OUD)","Inclusion Criteria:\n\n1. Male or female outpatients 18 years of age or older\n2. DSM-5 criteria for opioid use disorder\n3. Ability to access KIOS via smartphone or tablet\n4. Initiated buprenorphine treatment in the past 6 months\n\nExclusion Criteria:\n\n1. Unwilling or unable to comply with study requirements\n2. A psychiatric or medical condition interfering with ability to use the app\n3. Incarceration\n4. Suicide risk as determined by the treating medical clinician at the site",{"count":192,"type":23},134,[26],"The researchers will study the KIOS app, a digital health tool made to help people recovering from opioid addiction take better care of themselves. They want to see how the app works in real life and learn who benefits most from using it. The study will also ask participants what they think about the app and how easy it is to use.",[196],"Opioid Use Disorder",[198,199,200],"KIOS app","Digital health","Real-world impact","2026-07-21",{"date":203,"type":38},"2026-07-23",{"date":66,"type":23},{"date":206,"type":23},"2028-06-30",{"name":44,"class":45},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":24,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":46},"100647790","noninvasive-brain-stimulation-combined-with-written-exposure-therapy-for-ptsd-in-military-personnel-with-tbi-100647790","NCT07715799","Noninvasive Brain Stimulation Combined With Written Exposure Therapy for PTSD in Military Personnel With TBI","A Randomized Clinical Trial Using Noninvasive Brain Stimulation Combined With Written Exposure Therapy for PTSD in Military Personnel With TBI","Inclusion Criteria:\n\n1. U.S military service member or veteran (18-70 years old)\n2. PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale (CAPS-5-R)\n3. History of mild to moderate Traumatic Brain Injury (TBI)\n4. Able to speak, read, and write in English (due to assessment measures and writing intervention)\n\nExclusion Criteria:\n\n1. TBI that occurred within the past three months prior to the baseline assessment\n2. History of significant intracranial pathology (e.g., severe TBI)\n3. History of major neurological disorder (e.g., epilepsy, dementia)\n4. Metallic objects other than dental appliances\u002Ffillings above the shoulders.\n5. Electronic implants that could be susceptible to electrical current (e.g., cardiac pacemaker)\n6. History of skin condition at site of stimulation (e.g., psoriasis)\n7. Current suicidal ideation severe enough to warrant immediate attention\n8. Current manic episode or psychotic symptoms requiring immediate stabilization or hospitalization\n9. Current substance use requiring stabilization or hospitalization\n10. Change in anti-convulsive or benzodiazepine medication regimen in past month.\n11. History of adverse effects to previous noninvasive brain stimulation.\n12. Concurrent engagement in another noninvasive brain stimulation or trauma focused psychotherapy.\n13. Currently pregnant or breastfeeding.","70 Years",{"count":217,"type":23},150,[26],"In this study, the investigators are evaluating whether transcranial direct current stimulation (tDCS), a brain stimulation technique, can be combined with Written Exposure Therapy (WET), a standard talk therapy for posttraumatic stress disorder (PTSD) to improve treatment response and improve symptom of traumatic brain injury (TBI).\n\nAfter consenting to be in the study, participants will be asked to complete a baseline assessment of your psychological and physical health that will determine whether you are able to participate in the study. Following the baseline, you will be randomly assigned to receive tDCS or a sham\u002Fplacebo. Everyone will also participate in 5 weekly WET psychotherapy sessions for 5 consecutive weeks. The first appointment will be 90 minutes and the subsequent appointments will be 60 minutes. tDCS or sham\u002Fplacebo will occur during the writing portion of the session. All participants will also be asked to complete 1-, 3-, and 6-month posttreatment follow-up assessments.",[221],"Post Traumatic Stress Disorder",[223,224,225],"PTSD","Transcranial Direct Current Stimulation (tDCS)","Written Exposure Therapy (WET)","2026-07-16",{"date":228,"type":38},"2026-07-20",{"date":230,"type":23},"2026-09-30",{"date":232,"type":23},"2030-09-01",{"name":44,"class":45},{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":24,"phases":243,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":46},"100597300","phase-3-sglt2i-pioglitazone-and-ketone-production-in-t1d-100597300","NCT07056699","SGLT2i, Pioglitazone, and Ketone Production in T1D","Protocol V: San Antonio Site Sub Study: Can Pioglitazone Block SGLT2 Inhibitor-induced Stimulation of Lipolysis, Ketone Production and Liver Glucose Production in Type I Diabetic Patients","INCLUSION CRITERIA\n\n1. Age \\>18 years\n2. T1D\n3. Other than diabetes, subjects must be in good general health as determined by the investigator based on physical exam, medical history and screening labs.\n\n   Minor deviations may be permitted if:\n   * The abnormality is not considered clinically significant.\n   * The deviation does not pose a safety risk or interfere with study participation.\n   * The rationale for inclusion is documented in the source records.\n4. Fasting C-peptide concentration \\\u003C0.7 ng\u002Fml\n5. Poor glycemic control (HbA1c=7.0-11.0%)\n6. Treatment with multiple daily insulin injections (basal plus prandial) or insulin pump\n7. Total daily insulin dose ≥0.6 U\u002Fkg per day\n8. Stable insulin dose (±4 units) in the preceding three months\n9. eGFR ≥ 50 ml\u002Fmin\n10. Weight stable over the preceding 3 months (± 4 pounds)\n11. Positive GAD antibody (Glutamic Acid Decarboxylase antibody). \\*\n\n    * Testing for GAD antibodies will be performed during the screening visit. Participants who test positive for GAD antibodies will be eligible for enrollment in the study. Over time, these antibodies may disappear, reducing the likelihood of a positive result during screening. If participant tests negative for GAD antibodies, their medical history will be reviewed to determine whether testing for GAD antibodies was performed at an earlier stage of Type 1 Diabetes (T1D). If prior positive results are confirmed, the participant may be enrolled. If a participant tests positive for antibodies other than GAD, an exception request will be submitted to the Institutional Review Board (IRB) for approval.\n\nEXCLUSION CRITERIA\n\n1. Type 2 Diabetes (T2D)\n2. Daily insulin dose \\\u003C0.6 U\u002Fkg per day\n3. Fasting C-peptide \\>0.7 ng\u002Fml\n4. HbA1c \\\u003C7.0% or \\>11.0%\n5. eGFR \\\u003C 50 ml\u002Fmin\n6. Hematuria in urine analysis\n7. Pregnancy, lactating, positive pregnancy test or planning to become pregnant in the following year. Women of child-bearing potential will be required to undergo a pregnancy test prior to enrollment and must agree to use effective contraception (at least two barrier methods) for the duration of the study.\n8. Major organ system disease which includes: (i) malignancy or history of malignancy including bladder cancer; (ii) Congestive heart failure or history of coronary heart disease or any other cardiac disease; (iii) chronic liver disease or LFT \\>3 times the upper normal level; (iv) History of alcohol or drug abuse; (v) History of chronic lung disease (e.g., COPD, asthma); (vi) history of rheumatic disease; (vii) History of chronic pancreatitis or pancreatic surgery; (viii) History of CVA or TIA (ix) Planned surgery during the study; (x) history of HIV infection or other immune compromised disease; and history of organ transplantation; (xi) patients who take medications, other than insulin, known to affect glucose metabolism, e.g., prednisone.\n9. Evidence of proliferative diabetic retinopathy\n10. Patients enrolled in a heavy exercise program\n11. Patients on ketogenic diet\n12. History of hospitalization for DKA, hypoglycemia or uncontrolled hyperglycemia in the preceding 6 month.\n13. Presence of symptoms of poor glycemic control, e.g. polydipsia or polyurea\n14. History of hypersensitivity to dapagliflozin or pioglitazone\n15. Participants with a history of radiation exposure exceeding 5 REM within the previous 12 months will be excluded.\n\nPrior to the screening period, potential participants will be pre-screened either by phone or in person at the Texas Diabetes Institute. Individuals with prior significant radiation exposure will be excluded.",{"count":242,"type":23},24,[244],"PHASE3","Participants are being asked to be in a research study. Scientists do research to answer important questions which might help change or improve treatment of participants disease in the future.\n\nIn patients with Type 1 Diabetes (T1D), dapagliflozin a Selective Glucose Transporter 2 Inhibitor (SGLT2i) is known to increase production of glucose in the liver, increase breakdown of fats (lipolysis), and increase production of ketones (ketogenesis). Ketones are chemicals produced by the liver when the body breaks down fat for energy instead of glucose. When the level of ketones in the body becomes too high, a condition called ketoacidosis develops. In this study, the study team will investigate whether adding pioglitazone (a medication commonly used to treat type 2 diabetes), can reduce the dapagliflozin - induced liver glucose production, fat break down (lipolysis) and ketone body production (ketogenesis) in patients with T1D.",[247],"Type1diabetes",[249,250,251],"Selective Glucose Cotransporter 2 inhibitors (SGLT2i)","Dapagliflozin","Pioglitazone",{"date":228,"type":38},{"date":254,"type":38},"2026-07-01",{"date":256,"type":23},"2027-06-30",{"name":44,"class":45},{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":18,"minAge":266,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":24,"phases":270,"briefSummary":271,"conditions":272,"keywords":275,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":287},"100636443","early-phase-1-teapot-study-multisite-100636443","NCT07565753","TEAPOT Study Multisite","TranExamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage (TEAPOT): A Multi-center Feasibility Study","TEAPOT","Inclusion Criteria:\n\n1. Received a tonsillectomy\n2. Presents to the ED with secondary\\* post-tonsillectomy hemorrhage\n3. Children between age of 2 to 17 years of age (i.e., before their 18th birthday) \\*Secondary post-tonsillectomy hemorrhage is defined as greater than 24 hours from their primary tonsillectomy operation (arrival in recovery\u002FPACU).\n\nExclusion Criteria:\n\n1. Known and documented bleeding or clotting disorder.\n2. Known pregnancy.\n3. Patients with known hypersensitivity or allergic response to tranexamic acid.\n4. Parents or guardians who cannot communicate in English or Spanish.\n5. Intubation prior to enrollment.\n6. Previously enrolled patients.","2 Years","17 Years",{"count":269,"type":23},30,[116],"After a child has their tonsils removed, sometimes they might bleed which can be a problem. There is a special mist medicine called nebulized tranexamic acid (TXA) that might help stop the bleeding without having to touch the sore spot. If this mist works well, it could help kids get better by making sure they don't have to go back for more surgery or need blood from someone else. Not having another surgery is good because it means kids won't have to sleep under medicine again, which can sometimes be risky for their brains and breathing, and they won't feel as scared or hurt.",[273,274],"Hemorrhage, Surgical","Tonsillar Bleeding",[276,277,278],"Tranexamic Acid","Nebulizer","Post tonsillectomy hemorrhage","2026-07-15",{"date":281,"type":38},"2026-07-17",{"date":283,"type":38},"2026-07-14",{"date":285,"type":23},"2028-09-30",{"name":44,"class":45},3,{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":296,"targetDuration":4,"studyType":24,"phases":297,"briefSummary":298,"conditions":299,"keywords":301,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":74},"100632160","modulating-inflammation-in-neuro-trauma-100632160","NCT07510074","Modulating Inflammation in Neuro-Trauma","MINT: Modulating Inflammation in Neuro-Trauma","MINT","Inclusion Criteria:\n\n* Age 18-75 years old\n* Glasgow Coma Scale (GCS) Score 3-12\n* Expected Intensive Care Unit (ICU) stay \\> 48 hours\n* Presenting with acute Traumatic Brain Injury (TBI) within 24 hours\n\nExclusion Criteria:\n\n* Pregnant\n* Any electrical implanted device\n* Immunomodulatory medication\n* Human Immune Deficiency Virus (HIV) patients\n* Autoimmune disease\n* Known cancer immunotherapy\n* Past medical history of symptomatic bradycardia\n* Penetrating brain injury\n* Clinical team assessment of prognosis and imminent risk of death such as Decision to withdraw life-sustaining measures\n* Current incarceration\n* Trauma\u002FLaceration to the left ear",{"count":171,"type":23},[26],"MINT is a single-site, prospective, randomized, double-blind, sham-controlled pilot trial evaluating the safety and feasibility of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with moderate to severe traumatic brain injury (GCS 3-12). Participants will be randomized to receive either active taVNS or sham stimulation using the same device. The primary objective is to assess the safety and feasibility of taVNS implementation in the acute TBI setting. Secondary objectives include exploratory measurement of serum inflammatory and neuronal injury biomarkers and assessment of functional outcome using the Extended Glasgow Outcome Scale at hospital discharge.",[300],"Traumatic Brain Injury",[302,303,304],"Vagus nerve stimulation (VNS)","Inflammation","Cerebral edema",{"date":281,"type":38},{"date":307,"type":23},"2026-08",{"date":309,"type":23},"2027-03",{"name":44,"class":45},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":18,"minAge":318,"maxAge":20,"enrollmentInfo":319,"targetDuration":4,"studyType":24,"phases":321,"briefSummary":322,"conditions":323,"keywords":324,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":333,"locationsCount":46},"100597040","phase-1-sglt2i-pioglitazone-and-ketone-production-in-t2d-100597040","NCT07053319","SGLT2i, Pioglitazone, and Ketone Production in T2D","Protocol lV: SGLT2 Inhibitors, Pioglitazone and Ketone Production in Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Ages 30-75\n* BMI (Body Mass Index) 21-45 kg\u002Fm2\n* HbA1c = 7.0-11%\n* eGFR (estimated glomerular filtration rate)\\> 60 ml\u002Fmin\u002F1.73m2\n* Blood Pressure (BP)≤160\u002F90 mmHg\n* Participants must be in general good health based on medical history, physical exam, screening blood chemistries, CBC (Complete Blood Count), TSH\u002FT4 (thyroid\u002Fthyroxine hormone), EKG (electrocardiogram), and urinalysis (UA)\n* Stable body weight (±1.5 kg) over the last 3 months and must not participate in an excessively heavy exercise program\n* Patients treated with diet, Sulfonylureas, Metformin, or Sulfonylureas\u002FMetformin (Sulfo\u002FMET)\n* Participants receiving a Glucagon like peptide -1 receptor agonist (GLP1-RA) must be on a stable dose for at least three months prior to study enrollment.\n* Participants receiving a Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitor) must be on a stable dose for at least two months prior to study enrollment.\n* SGLT2 inhibitors must be discontinued at least two months prior to study enrollment.\n* Statin therapy is permissible if the dose has been stable for at least 3 months\n\nEXCLUSION CRITERIA\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Patients treated with Thiazolidinediones (TZDs), or Insulin are excluded.\n* Patients taking medications other than Sulfonylureas\u002FMetformin (SU\u002FMET), stable dose of GLP1-RA and DPP4i known to affect glucose metabolism are excluded. Patients taking SGLT2i within 2 months of screening visit will be excluded from participating in this study, however they may be asked whether they would agree to discontinue the medication for two months to become eligible. (Please see clarification below.) \\*\n* Subjects with evidence of proliferative retinopathy or estimated glomerular filtration rate (eGFR) \\\u003C 60 are excluded\n* Women of childbearing potential are excluded unless they are taking\u002Fusing appropriate contractive medications\u002Fdevices \\* Only participants who are taking SGLT2 inhibitors during the prescreening period will be asked to discontinue the medication at least two months prior to the screening visit. If they agree, they will return for an HbA1c measurement four weeks after stopping the SGLT2 inhibitor.\n\nIf their HbA1c rises to greater than 10%, treatment will be initiated with either metformin, a DPP-4 inhibitor, or a sulfonylurea. We do not anticipate any adverse effects during this initial period, provided the HbA1c remains below 10%.\n\nHbA1c will be measured using a fingerstick test, which requires only a minimal amount of blood. No compensation will be provided during this phase.\n\nAfter two months of medication discontinuation, participants will return for a screening visit. If they meet all eligibility criteria, they will be enrolled in the study and payment done by protocol.","30 Years",{"count":320,"type":23},64,[173],"To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).",[90],[325,326,327,328],"Endogenous glucose production","Ketogenesis","Gluconeogenesis","Lipolysis",{"date":281,"type":38},{"date":331,"type":38},"2026-05-11",{"date":256,"type":23},{"name":44,"class":45},{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":18,"minAge":318,"maxAge":20,"enrollmentInfo":341,"targetDuration":4,"studyType":24,"phases":343,"briefSummary":344,"conditions":345,"keywords":346,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":352,"locationsCount":46},"100597039","phase-1-sglt2i-ketoacidosis-volume-contraction-and-insulinopenia-100597039","NCT07053306","SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia","Protocol III: SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia","Patients with T2D\n\nInclusion Criteria:\n\n* Ages 30-75\n* BMI (Body Mass Index) 21-45 kg\u002Fm2\n* HbA1c = 7.0-11%\n* eGFR (estimated glomerular filtration rate)\\> 60 ml\u002Fmin\u002F1.73m2\n* Blood Pressure (BP)≤160\u002F90 mmHg\n* Participants must be in general good health based on medical history, physical exam, screening blood chemistries, CBC (Complete Blood Count), TSH\u002FT4 (thyroid\u002Fthyroxine hormone), EKG (electrocardiogram), and urinalysis (UA)\n* Stable body weight (±1.5 kg) over the last 3 months and must not participate in an excessively heavy exercise program\n* Patients treated with diet, Sulfonylureas, Metformin, or Sulfonylureas\u002FMetformin (Sulfo\u002FMET)\n* Participants receiving a Glucagon like peptide -1 receptor agonist (GLP1-RA) must be on a stable dose for at least three months prior to study enrollment.\n* Participants receiving a Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitor) must be on a stable dose for at least two months prior to study enrollment.\n* SGLT2 inhibitors must be discontinued at least two months prior to study enrollment.\n* Statin therapy is permissible if the dose has been stable for at least 3 months\n\nEXCLUSION CRITERIA\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Patients treated with Thiazolidinediones (TZDs), or Insulin are excluded.\n* Patients taking medications other than Sulfonylureas\u002FMetformin (SU\u002FMET), stable dose of GLP1-RA and DPP4i known to affect glucose metabolism are excluded. Patients taking SGLT2i within 2 months of screening visit will be excluded from participating in this study, however they may be asked whether they would agree to discontinue the medication for two months to become eligible. (Please see clarification below.) \\*\n* Subjects with evidence of proliferative retinopathy or estimated glomerular filtration rate (eGFR) \\\u003C 60 are excluded\n* Women of childbearing potential are excluded unless they are taking\u002Fusing appropriate contractive medications\u002Fdevices \\* Only participants who are taking SGLT2 inhibitors during the prescreening period will be asked to discontinue the medication at least two months prior to the screening visit. If they agree, they will return for an HbA1c measurement four weeks after stopping the SGLT2 inhibitor.\n\nIf their HbA1c rises to greater than 10%, treatment will be initiated with either metformin, a DPP-4 inhibitor, or a sulfonylurea. We do not anticipate any adverse effects during this initial period, provided the HbA1c remains below 10%.\n\nHbA1c will be measured using a fingerstick test, which requires only a minimal amount of blood. No compensation will be provided during this phase.\n\nAfter two months of medication discontinuation, participants will return for a screening visit. If they meet all eligibility criteria, they will be enrolled in the study and payment done by protocol.",{"count":342,"type":23},29,[173],"To examine the 2-HIT hypothesis that the SGLT2i-induced stimulation of EGP, lipolysis, and ketone production requires the combination of volume depletion plus insulinopenia in T2D individuals.",[90],[347,325,326,327,328],"Pancreatic clamp",{"date":281,"type":38},{"date":350,"type":38},"2025-04-29",{"date":256,"type":23},{"name":44,"class":45},{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":18,"minAge":318,"maxAge":20,"enrollmentInfo":360,"targetDuration":4,"studyType":24,"phases":362,"briefSummary":363,"conditions":364,"keywords":365,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":371,"locationsCount":46},"100597038","early-phase-1-sglt2i-hepatic-glucose-production-and-sns-100597038","NCT07053293","SGLT2i, Hepatic Glucose Production, and SNS","Protocol II: SGLT2i, Hepatic Glucose Production, and Sympathetic Nervous System (SNS)","Patients with T2D\n\nInclusion Criteria:\n\n* Ages 30-75\n* BMI (Body Mass Index) 21-45 kg\u002Fm2\n* HbA1c = 7.0-11%\n* eGFR (estimated glomerular filtration rate)\\> 60 ml\u002Fmin\u002F1.73m2\n* Blood Pressure (BP)≤160\u002F90 mmHg\n* Participants must be in general good health based on medical history, physical exam, screening blood chemistries, CBC (Complete Blood Count), TSH\u002FT4 (thyroid\u002Fthyroxine hormone), EKG (electrocardiogram), and urinalysis (UA)\n* Stable body weight (±1.5 kg) over the last 3 months and must not participate in an excessively heavy exercise program\n* Patients treated with diet, Sulfonylureas, Metformin, or Sulfonylureas\u002FMetformin (Sulfo\u002FMET)\n* Participants receiving a Glucagon like peptide -1 receptor agonist (GLP1-RA) must be on a stable dose for at least three months prior to study enrollment.\n* Participants receiving a Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitor) must be on a stable dose for at least two months prior to study enrollment.\n* SGLT2 inhibitors must be discontinued at least two months prior to study enrollment.\n\nEXCLUSION CRITERIA\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Patients treated with Thiazolidinediones (TZDs), or Insulin are excluded.\n* Patients taking medications other than Sulfonylureas\u002FMetformin (SU\u002FMET), stable dose of GLP1-RA and DPP4i known to affect glucose metabolism are excluded. Patients taking SGLT2i within 2 months of screening visit will be excluded from participating in this study, however they may be asked whether they would agree to discontinue the medication for two months to become eligible. (Please see clarification below.) \\*\n* Subjects with evidence of proliferative retinopathy or estimated glomerular filtration rate (eGFR) \\\u003C 60 are excluded\n* Women of childbearing potential are excluded unless they are taking\u002Fusing appropriate contractive medications\u002Fdevices \\* Only participants who are taking SGLT2 inhibitors during the prescreening period will be asked to discontinue the medication at least two months prior to the screening visit. If they agree, they will return for an HbA1c measurement four weeks after stopping the SGLT2 inhibitor.\n\nIf their HbA1c rises to greater than 10%, treatment will be initiated with either metformin, a DPP-4 inhibitor, or a sulfonylurea. We do not anticipate any adverse effects during this initial period, provided the HbA1c remains below 10%.\n\nHbA1c will be measured using a fingerstick test, which requires only a minimal amount of blood. No compensation will be provided during this phase.\n\nAfter two months of medication discontinuation, participants will return for a screening visit. If they meet all eligibility criteria, they will be enrolled in the study and payment done by protocol.",{"count":361,"type":23},22,[116],"In this study, PI will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) that the increases in ketone production and lipolysis can be prevented by concomitant administration of the thiazolidinedione pioglitazone. Principal Investigator (PI) will conduct five distinct experiments to test this hypothesis in patients with T2D.\n\nTo examine the role of the SNS on the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D by comparing the effect of empagliflozin versus empagliflozin plus propranolol.",[90],[325,326,327,328,366],"Norepinephrine turnover",{"date":281,"type":38},{"date":369,"type":38},"2025-01-07",{"date":256,"type":23},{"name":44,"class":45},{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":18,"minAge":318,"maxAge":20,"enrollmentInfo":378,"targetDuration":4,"studyType":24,"phases":379,"briefSummary":380,"conditions":381,"keywords":382,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":387,"locationsCount":46},"100513068","phase-1-sglti-hepatic-glucose-production-and-ketogenesis-100513068","NCT05960656","SGLTi, Hepatic Glucose Production and Ketogenesis","Protocol l: SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis",{"count":269,"type":23},[173],"In this study, we will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) and type 1 diabetes (T1D), and that the increases in ketone production and lipolysis can be prevented by concomitant administration of the thiazolidinedione pioglitazone. We will conduct five distinct experiments to test this hypothesis in patients with T2D and T1D.\n\nMAIN STUDY: To examine the effect of empagliflozin versus empagliflozin\u002Fpancreatic clamp on EGP (6,6, D2-glucose), gluconeogenesis (D2O), lipolysis (U-2H-glycerol), ketogenesis (13C-palmitate conversion to 3-betahydroxybuyrate), and norepinephrine turnover (3H-NE) in type 2 diabetes subjects.",[90],[347,325,326,327,328,366],{"date":281,"type":38},{"date":385,"type":38},"2023-10-05",{"date":256,"type":23},{"name":44,"class":45},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":395,"enrollmentInfo":396,"targetDuration":4,"studyType":24,"phases":398,"briefSummary":399,"conditions":400,"keywords":403,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":46},"100647871","free-soft-tissue-grafts-fstg-using-autograft-palatal-donor-tissue-vs-xenograft-collagen-matrix-zderm-100647871","NCT07713199","Free Soft Tissue Grafts FSTG) Using Autograft Palatal Donor Tissue vs. Xenograft Collagen Matrix (Zderm™)","Free Soft Tissue Grafts (FSTG) Using Autograft Palatal Donor Tissue vs. Xenograft Collagen Soft Tissue Matrix From Porcine Achilles Tendon (Zderm™)","Inclusion Criteria:\n\n* Male or female patient aged 18 to 89\n* One or more teeth\u002Fdental implants, excluding 3rd molars, that have been identified by dental faculty as requiring augmentation of KT\n* A FSTG is indicated and treatment planned to augment the KT. Coverage of exposed root surfaces is not indicated or intended. Patients needing root coverage surgical procedures re not eligible for enrollment (similar to our past studies, see references 11,12)\n* Female patients who have undergone a hysterectomy, tubal ligation, or menopause, and non-pregnant women of child-bearing potential as eligible.\n* Patients who are nonsmokers or former smokers are eligible. Current smokers may also be included if they smoke \\\u003C10 cigarettes per day (less than or equal to 10 cigarettes per day).\n\nExclusion Criteria:\n\n* Patients with a known allergy to collagen of animal origins.\n* Patients who will not cooperate with the follow-up schedule.\n* Patients will not be entered who are mentally incompetent, prisoners, or pregnant.\n* Patients who require soft tissue grafting specifically to treat exposed root coverage (gingival recession)\n* Pregnant women or women intending to become pregnant during the study period (as confirmed verbally; an over-the-counter pregnancy test will be provided if pregnancy status is unknown or suspected).\n* Patients who become pregnant during the study will be withdrawn and standard care will be delivered.\n* Patients with active or systemic infections other than periodontitis; a disease entity, condition or therapeutic regimen which decreases probability of soft tissue healing, e.g., poorly controlled diabetes, autoimmune diseases, long-term steroid therapy.\n* Smokers who smoke \\>10 cigarettes per day (more than 10 cigarettes per day)","89 Years",{"count":397,"type":23},68,[26],"Participant in this study are asked to participate because they have teeth or dental implants that were identified as having very little gum tissue and would benefit from gum tissue graft surgery. This study has 2 treatment groups that differ only in the material that will be used at the graft site:\n\n* Gum tissue taken from the patient's own palate\n* Commercially available collagen matrix derived from porcine (pig) Achilles tendon (FDA-approved for the surgery done in this study).\n\nBoth materials have been in use in dental practices for many years, but no studies have directly compared the outcomes between palatal tissue and the porcine collagen matrix we will use in this study.\n\nParticipants will be randomized into one of the 2 groups using sealed envelopes (the process is like flipping a coin). All the study visits will take place during regular dental appointments that would be scheduled even if not participating in this research.",[401,402],"Gingival Recession Localized Moderate","Dental Implant",[404,405,406],"Tissue graft surgery","Receding gums","Keratinized tissue",{"date":228,"type":38},{"date":409,"type":23},"2026-09-15",{"date":411,"type":23},"2029-01-31",{"name":44,"class":45},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":215,"enrollmentInfo":420,"targetDuration":4,"studyType":24,"phases":422,"briefSummary":423,"conditions":424,"keywords":428,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":436,"leadSponsor":438,"locationsCount":46},"100647404","oil-pulling-reduction-100647404","NCT07706647","Oil Pulling Reduction","Evaluation of Oil Pulling Mouthwash for Reduction of Dental Plaque, Gingivitis, and Selective Reduction of Bacteria","Inclusion Criteria:\n\n1. Adult subjects aged 18-70, that are in good health.\n2. Subject must have:\n\n   1. Baseline gingival inflammation (MGI) score of at least 1.80.\n   2. Baseline gingival bleeding (GBI) score of ≥ 1 on at least 20 sites.\n3. An overnight (12 to 18 hour abstention from any oral hygiene) dental plaque (mean) score greater than 0.6 according to the RMNPI Index.\n4. Have a minimum of 20 'scorable' teeth (excluding 3rd molars).\n5. The subjects should understand the information provided about the investigative nature of the treatment, possible benefits and side effects. Subjects will sign the Informed Consent Form.\n6. The subjects should be willing to comply with the study procedure and schedule, including the follow-up visits.\n\nExclusion Criteria:\n\n1. Current or history of oral cavity cancer or oropharyngeal cancer.\n2. Subject with destructive periodontal disease or those on antibiotic or anti-inflammatory drugs.\n3. Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body.\n4. Pregnant or nursing by subject report.\n5. Known allergic reaction to any of the study mouthwashes or any of their component.\n6. Any active condition, including but not limited to advanced periodontal disease or severe gingival recession, in the oral cavity at the discretion of the investigator.\n7. Any surgery or recent dental procedure in the oral cavity within 3 months prior to treatment, or before complete healing.\n8. Subjects that do not brush regularly.\n9. Any condition that might make it unsafe for the subject to participate in this study, at the discretion of the investigator.\n10. History of allergy or hypersensitivity to mouthwash ingredients\n11. Significant medical conditions, such as uncontrolled diabetes or immunosuppressive disorders\n12. Use of tobacco products, including cigarettes and smokeless tobacco\n13. Presence of orthodontic appliances, except for removable retainers\n14. Participation in another clinical trial within the last 30 days.\n15. Individuals unable to comply with study requirements, such as regular product use or scheduled visits.\n16. Habitual use of alcohol or drugs that may affect compliance or oral health",{"count":421,"type":23},120,[26],"The goal of this study is to scientifically evaluate the efficacy of this oil pulling oral rinse in reducing dental plaque, gingival inflammation, gingival bleeding, and selectively reducing caries- and periodontal disease-associated bacteria compared to a marketed mouthwash and a placebo oral rinse",[425,426,427],"Good Health","Gingival Inflammation and Bleeding","Dental Plaque",[429,430,431,432],"mouthwash","gingivitis","plaque","dental","2026-07-11",{"date":226,"type":38},{"date":254,"type":23},{"date":437,"type":23},"2026-10-31",{"name":44,"class":45},{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":24,"phases":449,"briefSummary":450,"conditions":451,"keywords":453,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":46},"100647515","advancing-skills-through-consultation-education-and-novel-technologies-100647515","NCT07707102","Advancing Skills Through Consultation, Education, and Novel Technologies","Increasing the Reach of Evidence-Based PTSD Treatment: Development and Clinical Trial of Artificial Intelligence (AI)-Facilitated, Web-Based Written Exposure Therapy Training","ASCENT","Inclusion Criteria:\n\n1. mental health provider;\n2. serves veterans and\u002For service members with PTSD (by self-report);\n3. willing to participate in either live or web-based training.\n\nExclusion Criteria:\n\n1\\. has already completed formal training in Written Exposure Therapy",{"count":448,"type":23},300,[26],"This research study tests strategies to train behavioral health providers in Written Exposure Therapy (WET), an evidence-based treatment for posttraumatic stress disorder (PTSD). There are a number of evidence-based treatments for posttraumatic stress disorder (PTSD). However, most behavioral health providers have not received training in these PTSD treatments and do not offer them regularly to their patients.\n\nThe researchers hope to learn about the optimal way to train behavioral providers in this type of treatment. This study is designed to determine the comparative effectiveness of different training strategies on key outcomes such as how much competency providers develop in the therapy and to how many patients they deliver the therapy. This study will help the researchers understand if we can help more providers learn to competently delivery Written Exposure Therapy by using strategies that are more convenient and cost less money, including web-based and AI-facilitated training supports. This study will also help us learn which training strategies work best for which providers so that in the future we can make personalized training recommendations.",[452],"PTSD - Post Traumatic Stress Disorder",[454,455],"Written Exposure Therapy","AI-facilitated training","2026-07-10",{"date":226,"type":38},{"date":459,"type":23},"2026-08-03",{"date":461,"type":23},"2028-08-31",{"name":44,"class":45},{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":469,"minAge":19,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":24,"phases":472,"briefSummary":473,"conditions":474,"keywords":476,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":46},"100647164","mhealth-to-improve-medication-adherence-among-latina-breast-cancer-patients-experiencing-non-medical-drivers-of-health-100647164","NCT07706127","mHealth to Improve Medication Adherence Among Latina Breast Cancer Patients Experiencing Non-Medical Drivers of Health","Inclusion Criteria:\n\nEnglish- or Spanish-speaking Latina patients aged 18 and older who:\n\na) are diagnosed with hormone receptor-positive breast cancer and prescribed HT; b) within 1 to 24 months of starting HT; c) are experiencing any NMDoH by the Avanzando Center NMDoH Screener; d) are able to read; e) own a smartphone and are able to send and receive text messages and access the Internet; and f) are able to provide informed consent to participate in the study.\n\nExclusion Criteria:\n\nNot meeting the criteria above, or patients who:\n\na) are not Latina and are younger than 18 years; b) are not receiving HT treatment; c) with more than 24 months of starting treatment; d) do not experience any NMDoH by the Avanzando Center NMDoH Screener; e) are unable to read; f) do not own a smartphone and are unable to send and receive text messages and access the Internet; g) are unable to respond to text messages and questions or unable to download the study app; h) are unable to provide informed consent due to a mental, emotional, or physical handicap that keeps them from understanding the consent information; i) are unable to see the app and study materials and videos (i.e., are blind, deaf); and j) currently participating in a psychosocial intervention trial or individual\u002Fgroup psychotherapy.","FEMALE",{"count":471,"type":23},159,[26],"Background: Hormonal therapy (HT) is highly effective for nearly all breast cancer patients with hormone receptor-positive tumors, which are about 80% of all breast cancer diagnoses. Long-term use of HT reduces cancer recurrence rates and cuts the risk of mortality nearly in half during the second decade after diagnosis. Despite proven benefits, 33% of women who are prescribed HT do not take it as prescribed (\\\u003C80% take their daily dosage). Latina patients are disproportionately affected by non-medical drivers of health (NMDoH) that keep them from adhering to HT and are at higher risk of breast cancer recurrence and mortality.\n\nObjective: The goal of this 4-year randomized controlled study is to assess the effectiveness of the bilingual, culturally tailored, interactive HT Helper App, in combination with patient navigation (PN), on improving adherence to HT among Latina breast cancer patients experiencing any NMDoH barriers, such as income, health insurance, education, health literacy, and language, that impact their medication adherence. This theory-based intervention will increase patient education, enhance self-efficacy, facilitate communication with the medical team and coordination of resources to address NMDoH barriers, and help patients develop self-care skills for optimal adherence to HT, ensuring patients the most equitable treatment outcomes possible, including improvement in quality of life, survival, and life expectancy.\n\nSpecific Aims\u002FHypothesis: 1) Conduct a 3-group randomized study to assess the effectiveness of the HT Helper App + PN vs. PN alone vs. usual care, on HT adherence; and 2) Assess the effect of each study condition on patient self-efficacy to identify side effects, use self-care to manage side effects, and communicate with the medical team. We hypothesize that the HT Helper App + PN and the PN alone groups will have greater rates of HT adherence and higher patient self-efficacy than the usual care group; with the HT Helper App + PN achieving better results than both PN alone and the usual care groups.\n\nStudy Design. The proposed study involves a parallel 3-group randomized controlled trial with 5-time assessments (baseline, 3, 6, 12, and 18 months) and will enroll 159 breast cancer patients who are prescribed HT and are attending the breast clinic at the Mays Cancer Center at UT Health San Antonio. Intervention components are based on Social Cognitive Theory and elements of Motivational Interviewing.\n\nCancer Relevance. This innovative multi-level intervention will improve adherence to HT by addressing NMDoH and promote equitable breast cancer outcomes, including reduced recurrence and improved quality of life, overall survival, and life expectancy among underserved Latina patients. The anticipated outcome is a scalable, evidence-based, and easily disseminated intervention with potentially broad use to patients using oral anticancer medications.",[475],"Treatment Adherence",[477,478,479,480,481,482],"phone app","breast cancer hormone therapy","treatment adherence","Latinas","non-medical drivers of health","patient navigation","2026-07-09",{"date":279,"type":38},{"date":486,"type":38},"2025-09-26",{"date":488,"type":23},"2028-04-30",{"name":44,"class":45},{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":18,"minAge":497,"maxAge":498,"enrollmentInfo":499,"targetDuration":4,"studyType":24,"phases":500,"briefSummary":501,"conditions":502,"keywords":504,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":46},"100623791","tms-for-ptsd-in-youth-100623791","NCT07401225","TMS for PTSD in Youth","Transcranial Magnetic Stimulation as Treatment for Persistent PTSD in Texas Youth","Inclusion Criteria:\n\n1. Males and females; Age 12-20\n2. Have previously completed at least 9 sessions of trauma-focused therapy in our clinical trial or in the community\n3. Have current self-reported symptom score of 20 or greater on the UCLA PTSD Reaction index\n4. Willing to attend 10 TMS treatment sessions within a 30-day period\n5. Fluent in English\n\nExclusion Criteria:\n\n1. History of seizures\n2. History of head injury with loss of consciousness and concussive sequelae\n3. Brain abnormality such as tumor or other observable abnormality\n4. Currently receiving psychotherapy or TMS treatment\n5. Currently pregnant\n6. MRI contraindications (metal in body, orthodontic braces)\n7. Diagnosis of bipolar 1 or a psychotic disorder","12 Years","20 Years",{"count":142,"type":23},[26],"The purpose of this study is to test whether transcranial magnetic stimulation, or TMS, is an acceptable and helpful treatment for ongoing symptoms of posttraumatic stress syndrome disorder (PTSD) in 12-20 year olds. Ongoing PTSD refers to symptoms that continue after completing trauma-focused psychotherapy. About 1 in 4 patients need additional help to overcome PTSD after completing psychotherapy. Currently, scientists do not know the best way to help adolescents with persistent PTSD, and this study will test TMS as a possible treatment, and hopefully lead to future studies including more people.",[503],"Post Traumatic Stress Disorder (PTSD)",[505,506],"Transcranial Magnetic Stimulation","Transcranial Magnetic Stimulation (TMS)",{"date":508,"type":38},"2026-07-13",{"date":510,"type":38},"2026-05-09",{"date":512,"type":23},"2027-08-31",{"name":44,"class":45},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":521,"maxAge":522,"enrollmentInfo":523,"targetDuration":4,"studyType":24,"phases":525,"briefSummary":526,"conditions":527,"keywords":529,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":534,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":46},"100620345","swallowfit-study-in-parkinsons-disease-100620345","NCT07356414","SwallowFIT Study in Parkinson's Disease","\"SwallowFit,\" an Exercise Program and Randomized Clinical Trial Designed for US Service Members, Veterans, and Families Affected by Parkinson's Disease.","Inclusion Criteria:\n\n1. Adult S-VWP between \\>35-90 years of age\n2. Diagnosis of Idiopathic Parkinson's Disease \\[IDP\\] (either or suspected, tremor-predominant or rigid predominant)\n3. Disability level of Hoehn \\& Yahr stages II-III as indicated in their most recent neurological evaluation\n4. Swallowing concern, confirmed by Modified Unified Parkinson Disease Rating Scale \\[MDS-UPDRS\\]-\n5. ADL swallowing item \\>0, or Mann Assessment of Swallowing scale \\[MASA\\] score ≤185.\n6. Able to consume oral nutrition \\[Functional Oral Intake Score ≤ 6\\]\n7. Ambulatory\n8. No change of medication for at least 4 weeks before study inclusion\n\nExclusion Criteria:\n\n1. Classified as Hoehn and Yahr stages IV\n2. Unable to follow 2 step commands\n3. History of other neurological disease potentially causing dysphagia\n4. Dementia (MMSE\\\u003C20; Montreal cognitive assessment (MoCA) ≤ 20)\n5. Severe depression (BDI\\>19)\n6. Severe dyskinesia of head and neck (resulting in problems with MBSS recording)\n7. Severe documented Gastrointestinal disease\n8. History of Gastro-esophageal surgery\n9. History of Head or neck cancer with swallowing impairment or surgical intervention\n10. History of breathing disorders or diseases (e.g., Asthma, chronic obstructive pulmonary disease (COPD) requiring assistive breathing support.\n11. Untreated hypertension\n12. Heart disease requiring restricted activity and medical intervention\n13. Speech therapy intervention for swallowing within the past three months\n14. Women who are pregnant, nursing, or who plan to become pregnant during the study","35 Years","90 Years",{"count":524,"type":23},80,[26],"The goal of this clinical trial is to learn if a proactive swallow exercise will help to improve swallow fitness in patients with Parkinson's disease.\n\nThe aim of the study is to assess how effective this exercise is and to measure the change in swallowing fitness from the beginning to the end of the study.\n\nPatients who are given the exercise training will be compared to participants who are treated using the usual standard treatment.\n\nPatients will have 6 weeks of twice-weekly SwallowFIT training. Each session will be an hour long.",[528],"PARKINSON DISEASE (Disorder)",[530,531,532,533],"Swallowing","US Service members","Veterans","SwallowFIT",{"date":508,"type":38},{"date":536,"type":23},"2026-08-30",{"date":538,"type":23},"2028-06-29",{"name":44,"class":45},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":215,"enrollmentInfo":547,"targetDuration":4,"studyType":24,"phases":549,"briefSummary":550,"conditions":551,"keywords":553,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":567},"100486949","multisite-advancement-of-research-on-chronic-posttraumatic-headache-100486949","NCT05620719","Multisite Advancement of Research on Chronic Posttraumatic Headache","Project MARCH: Multisite Advancement of Research on Chronic Posttraumatic Headache","Inclusion Criteria:\n\n* Any veteran or active duty service member (DEERS-eligible; age 18 to 70 years) with mild or moderate TBI whose headache began or exacerbated within 3 months of a head or neck injury.\n* Headache meets ICHD-3 A5.2 criterion for delayed-onset persistent headache attributable to mild or moderate TBI and PTH is ongoing at enrollment (most recent headache within the past 2 weeks).\n* At least moderate to severe headache-related disability based on a HIT-6 score greater than 50.\n* Participant is stable on headache medication at baseline assessment (i.e., no changes in medication prescriptions in the past 4 weeks or study physician clinical judgement confirms stability; this includes botulinum toxin injections and devices like Cefaly).\n* Participant has a phone where they can receive reminders and complete the on-line Headache Diaries.\n* Participant speaks and reads\u002Funderstands English well enough to fully participate in the intervention and to reliably complete assessment measures.\n\nExclusion Criteria:\n\n* Participant reports a significant change in headache symptoms within 4 weeks of screening or has another secondary headache that may account for symptoms.\n* Participant has medication overuse headache based on Structured Diagnostic Headache Interview-Revised (Brief Version; SDIH-R) and clinical judgment.\n* Participant has a psychiatric problem that warrants immediate treatment as indicated in the electronic health record, flagged study during testing, or confirmed by a clinician through screening or review of clinical notes.\n* Participant demonstrates significant cognitive impairment that could impact treatment adherence\u002Fbenefit.",{"count":548,"type":23},525,[26],"Posttraumatic headache (PTH) is a common and highly disabling consequence of traumatic brain injury (TBI) in U.S. military service members and veterans. Cognitive Behavioral Therapy for PTH has been shown to significantly improve disability outcomes in veterans with persistent PTH when delivered in-person. Telemedicine platforms can dramatically increase access to evidence-based care. However, whether CBT for PTH retains its effectiveness when delivered through a telemedicine platform has yet to be established. The purpose of this 3-arm randomized clinical trial is to compare Clinic-based Cognitive-Behavioral Therapy (CCBT) to Telemedicine-based Cognitive Behavioral Therapy (TCBT) and to treatment as usual (TAU) in 525 service members and veterans with chronic posttraumatic headaches (PTH) at 4 VA medical centers\\* and 3 military treatment facilities across the U.S. Participants will be assessed for headache-related disability, headache experience, and psychiatric comorbidities across multiple time points.\n\n\\*VA Palo Alto Health Care System is temporarily randomizing into TAU and TCBT only.",[552],"Posttraumatic Headache",[554,555,532,556,557,558],"Cognitive Behavioral Therapy","Telehealth","Military Service Members","Chronic Pain","Headaches","2026-06-22",{"date":561,"type":38},"2026-06-26",{"date":563,"type":38},"2023-08-24",{"date":565,"type":23},"2027-08",{"name":44,"class":45},8,{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":575,"enrollmentInfo":576,"targetDuration":4,"studyType":24,"phases":577,"briefSummary":578,"conditions":579,"keywords":582,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":594,"locationsCount":46},"100644091","oil-pulling-whitening-mouthwash-100644091","NCT07667088","Oil Pulling Whitening Mouthwash","Evaluation of Tooth Whitening Efficacy of GuruNanda Oil Pulling Oral Rinse.","Inclusion Criteria:\n\n1. Adult subjects aged 18-60, that are in good health.\n2. Subject must have at least 2 natural anterior teeth, each having a mean Lobene composite score of ≥ 1.5 on the facial surfaces as assessed by the Investigator.\n3. Subject's front teeth shade should be 9 or darker (meaning shade score should be between 9 and 29), as assessed by the Vita bleachguide 3D-Master and the Vita EasyShade device.\n4. Subjects should understand the information provided about the investigative nature of the treatment, possible benefits and side effects. Subjects will sign the Informed Consent Form.\n5. The subjects should be willing to comply with the study procedure and schedule, including the follow up visits, and will refrain from using any other teeth whitening technologies during this period.\n6. The subject did not perform any procedure for teeth whitening (either at home or in clinic) at least 3 years prior to participating in the study.\n\nExclusion Criteria:\n\n1. Pregnant or nursing by subject report.\n2. Known allergic reaction to any of the study mouthwashes or any of their components. Participant has completed the screening questionnaire (Exclusion due to Known Allergens).\n3. Any active condition in the oral cavity at the discretion of the investigator.\n4. Any surgery or dental procedure in the treated area within 3 months prior to treatment, or before complete healing.\n5. Subjects that do not brush regularly.\n6. Any condition that might make it unsafe for the subject to participate in the study, at the discretion of the investigator.\n7. Heavy tobacco use, including cigarettes, cigars, or smokeless tobacco.\n8. Consumption of stain-causing substances (e.g., red wine, coffee, tea) that cannot be avoided during the study period.\n9. Use of medications that may affect tooth discoloration (e.g., tetracyclines, chlorhexidine).\n10. Participation in another clinical trial within the last 30 days.\n11. Presence of orthodontic appliances, except for removable retainers.\n12. Signs of advanced enamel wear, dentin exposure, or tooth fractures.","60 Years",{"count":421,"type":23},[26],"The goal of this study is to evaluate the tooth whitening efficacy of Oil Pulling oral rinse compared to a competitor's whitening mouthwash and a water-based mouthwash (placebo). Each participant will use one of three mouthwashes: GuruNanda Oil Pulling oral rinse (test), Competitor's mouthwash (positive), Water-based oral rinse (placebo). All mouthwashes will be used once daily last thing before bed at night. Data will be collected on tooth shade evaluated on the anterior teeth.",[580,581],"Healthy Adult Participants","Tooth Stain",[583,584,585,429,586,587],"tooth whitening","tooth stains","oil pulling","mouth rinse","stain removal","2026-06-18",{"date":590,"type":38},"2026-06-24",{"date":592,"type":38},"2026-05-01",{"date":40,"type":23},{"name":44,"class":45},{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":602,"enrollmentInfo":603,"targetDuration":4,"studyType":605,"phases":4,"briefSummary":606,"conditions":607,"keywords":608,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":618,"locationsCount":74},"100643969","the-effects-of-stellate-ganglion-block-sleep-in-us-active-duty-service-members-and-veterans-receiving-prolonged-exposure-therapy-for-ptsd-100643969","NCT07667309","The Effects of Stellate Ganglion Block Sleep in U.S. Active Duty Service Members and Veterans Receiving Prolonged Exposure Therapy for PTSD","The Effects of Stellate Ganglion Block on Sleep in U.S. Active Duty Service Members and Veterans Receiving Prolonged Exposure Therapy for Posttraumatic Stress Disorder (PTSD)","Inclusion Criteria:\n\n1. Ability to provide informed consent and follow study-related instructions.\n2. Be randomized into the study titled \"Combining Stellate Ganglion Block with Prolonged Exposure for PTSD: A Randomized Clinical Trial.\" NCT05889741\n3. Indicates willingness to wear the Sleep Profiler sleep monitor and to complete self-report assessments.\n\nExclusion Criteria:\n\n1\\. Pre-existing skin or soft tissue condition that precludes the ability to wear the Sleep Profiler headband.","65 Years",{"count":604,"type":23},40,"OBSERVATIONAL","Participants in this study will have already been enrolled in another research study: Combining Stellate Ganglion Block with Prolonged Exposure for PTSD, NCT05889741. The investigators are using a Sleep Profiler, EEG headband to monitor a participants brainwaves while they sleep to see what effects the Stellate Ganglion Block injection has on their sleep. Participants will wear the headband for 3 nights before the injection and then 3 nights after the injection. Participants will also complete self-report questionnaires regarding their sleep prior to the injection and following the injection. Approximately 40 participants will be included in this study. This study is a nested observational study whereby participants in the parent study who elect to participate will have their sleep assessed using the EEG headband device and self-reported sleep measures performed.",[59],[609,610,223,611,612],"Stellate Ganglion Block","Sleep Profiler","Sleep","Sleep architecture",{"date":614,"type":38},"2026-06-25",{"date":616,"type":23},"2026-06-15",{"date":256,"type":23},{"name":44,"class":45},{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":4,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":626,"targetDuration":4,"studyType":24,"phases":628,"briefSummary":629,"conditions":630,"keywords":632,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":639,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":74},"100591229","phase-1-loncastuximab-and-roflumilast-added-to-r-chop-lo-rituximab-and-roflumilast-rr-chop-for-nave-high-risk-diffuse-large-b-cell-lymphoma-dlbcl-100591229","NCT06977711","Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)","Phase Ib Clinical Trial of Loncastuximab and Roflumilast Added to R-CHOP (Lo-RR-CHOP) for Treatment Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)","Inclusion Criteria:\n\n1. Men and women 18 years of age or older.\n2. Pathologically proven diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS).\n\n   \\- Patients with Diffuse large B-cell lymphoma\u002F high grade B-cell lymphoma with MYC (myelocytomatosis oncogene) and BCL2 (B-cell lymphoma 2) rearrangements are allowed.\n3. No prior systemic therapy for lymphoma.\n4. Subject has provided informed consent.\n5. Subject is willing and able to comply with clinic visits and procedure outlined in the study protocol.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n7. Life expectancy of ≥3 months.\n8. Ann Arbor stage II-IV\n9. National Comprehensive Cancer Network - International Prognostic Index (NCCN-IPI) risk score of ≥ 2\n10. Measurable disease, meaning at least 1 lymph node or other lymphomatous lesion with a long axis of ≥1.5 cm by CT imaging, and at least one FDG-avid lesion by FDG-PET scan.\n11. Left ventricular ejection fraction of at least 45% by either echocardiography or radionucleotide angiography.\n12. Ability to swallow oral tablets without difficulty.\n13. All subjects with preserved reproductive potential must agree to practice abstinence or employ contraceptive measures for the duration of treatment and for 10 months (if female) or 7 months (if male) following final dosing. All male subjects are considered to have reproductive potential.\n\n    Female subjects of reproductive potential are those who:\n\n    i) are not at least 50 years old and have no menses for 24 consecutive months; or ii) have not been rendered surgically sterile (having undergone hysterectomy and\u002For bilateral salpingo-oophorectomy).\n\n    Female subjects of reproductive potential must have a negative serum pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin (hCG) within 7 days of first day of drug dosing.\n14. Meet the following clinical laboratory requirements:\n\n    * Creatinine clearance ≥30 ml\u002Fmin by Cockcroft-Gault formula;\n    * Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (unless indirect bilirubin is elevated due to Gilbert's syndrome or hemolysis);\n    * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤ 3 × ULN;\n    * Platelet count ≥ 50,000\u002FµL, with or without transfusion support;\n    * Absolute Neutrophil Count (ANC) ≥ 1000\u002FµL, with or without chronic granulocyte growth factor support;\n    * Hemoglobin ≥8 g\u002FdL, with or without transfusion support.\n\nExclusion Criteria:\n\n1. Allergy or intolerance to roflumilast.\n2. Allergy or intolerance to loncastuximab\n3. Any active malignancy other than DLBCL\n4. Current participation in another interventional clinical study\n5. Prior allogeneic bone marrow transplant within 12 months of screening date.\n6. Prior autologous stem cell transplant within 6 months of screening date.\n7. Immunotherapy, chemotherapy, radiotherapy, or investigational therapy within 6 months prior to drug dosing.\n8. Active central nervous system (CNS) involvement by lymphoma, including untreated symptomatic epidural disease.\n9. Active uncontrolled infection.\n10. Poorly controlled depressive symptoms and\u002F or currently under management for depression that is poorly controlled.\n11. Significant disease or medical conditions, as assessed by the Investigator and Sponsor, that would substantially increase the risk benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction within the last 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections, and congestive heart failure New York Heart Association Class III-IV.\n12. Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which subjects are not on active anti-cancer therapies and have had no evidence of active malignancy for at least 1 year.\n13. History of major surgery within 3 weeks or minor surgery within 1 week of roflumilast administration. Major surgery includes, for example, any open or laparoscopic entry into a body cavity, or operative repair of fracture; minor surgery includes, for example, open surgical biopsy of palpable\u002Fsuperficial lymph node, or placement of vascular access device.\n14. Other medical or psychiatric illnesses or organ dysfunction, which in the opinion of the investigator, would either compromise the subject's safety or interfere with the evaluation of the safety of the study agent.\n15. Corrected QT interval (QTc) prolongation (defined as a QTc \\>450 ms for males and \\>470 ms for females -Fridericia's correction-) or other clinically significant ECG abnormalities as assessed by the investigator.\n16. Baseline serum troponin above the upper limit of normal.\n17. Baseline serum brain natriuretic peptide (BNP )above the age-adjusted upper limit of normal.\n18. Baseline amylase above the upper limit of normal.\n19. Subjects known to be HIV-positive must not have multi-drug resistant HIV infection, cluster of differentiation 4 (CD4) counts \\\u003C 150\u002Fµl or other concurrent AIDS-defining conditions. Serologic screening for HIV is required within the 6 months prior to study enrollment.\n20. Subjects positive for Hepatitis B surface antigen (HBsAg) or Hepatitis C-virus ribonucleic acid (HCV RNA), unless both AST and ALT≤1.25 x ULN and there is no known history of chronic active hepatitis.\n\n    Serologic screening for hepatitis B and C testing is required within the 6 months prior to study enrollment.\n21. Subjects with moderate or severe liver impairment, as defined by a Child-Pugh class of B or C.\n22. Women who are pregnant or breastfeeding.\n23. Current use of any of the following medications: boceprevir, carbamazepine, ciprofloxacin, cobicistat, conivaptan, enzalutamide, fluvoxamine, itraconazole, ketoconazole, mitotane, phenytoin, posaconazole, rifampin, ritonavir, St. John's Wort, telaprevir, voriconazole, or zafirlukast.\n24. Current use of non-nucleoside reverse transcriptase inhibitors (NNRTI) including efavirenz, rilpivirine, etravirine, delavirdine, nevirapine, and lersivirine.",{"count":627,"type":23},10,[173],"This study is developed by the investigator and is a, phase I, single arm, clinical trial that will enroll subjects with untreated diffuse large B-cell lymphoma (DLCBL) at high risk for poor outcome. The types of treatments given will be shared with participants.\n\nThe aims are:\n\n1. To assess the safety and how well the participants tolerate the treatment\n2. Assess the response of the tumor to treatment to estimate complete response\n3. Assess the response of the tumor to treatment to estimate progression-free survival",[631],"Diffuse Large B-cell Lymphoma",[633,634,635,636,637,638],"Lymphoid neoplasms","Loncastuximab","Rituximab","Roflumilast","Lo-RR-CHOP","R-CHOP",{"date":559,"type":38},{"date":641,"type":38},"2025-06-20",{"date":643,"type":23},"2027-04-01",{"name":44,"class":45},""]